Healthcare ETFs Face-Off: Stability vs. Biotech Growth, Which Strategy Wins?

For investors looking to tap into the healthcare sector, the menu of exchange-traded funds has never been more extensive—or more confusing. A trio of recent analyses from The Motley Fool pits some of the most popular healthcare ETFs against each other, highlighting a fundamental split: the steady, dividend-paying giants of traditional pharmaceuticals versus the high-octane, high-risk world of biotechnology.

The core question is simple. Is it better to anchor a portfolio with broad, defensive healthcare exposure, or to chase the explosive growth that can come from a single successful drug trial? The answer, according to the data, depends entirely on an investor’s timeline, risk tolerance, and income needs.

The Stability Plays: XLV, IYH, and IHE

On one side of the ring are the broad-based and large-cap pharmaceutical funds. The State Street Health Care Select Sector SPDR ETF (XLV), a giant with over $41.7 billion in assets under management, offers exposure to 60 of the largest U.S. healthcare companies. Its top holdings read like a who’s who of the industry: Eli Lilly (LLY) at 16.39%, Johnson & Johnson (JNJ) at 10.80%, and AbbVie (ABBV) at 7.61%. Launched in 1998, XLV has delivered a lifetime total return of 864%, a compound annual growth rate (CAGR) of 8.6%, nearly matching the S&P 500’s 8.8% CAGR over the same period. Its expense ratio is razor-thin at 0.08%, and it offers a trailing-12-month dividend yield of 1.60%.

The iShares U.S. Healthcare ETF (IYH) takes a similar, though more concentrated, approach. With 100 holdings, its top five stocks—Eli Lilly, Johnson & Johnson, AbbVie, UnitedHealth Group, and Merck—account for roughly 45% of the fund’s total exposure. IYH has generated a 10-year total return of 153%, a CAGR of 9.7%, though that has significantly lagged the S&P 500’s 317% return over the same decade. The fund carries an expense ratio of 0.38% and yields 1.20%.

For investors who want to drill down even further into pure-play drug manufacturing, the iShares U.S. Pharmaceuticals ETF (IHE) offers a highly concentrated portfolio of just 56 stocks. Johnson & Johnson and Eli Lilly alone make up over 44% of the fund’s assets. This focus on established, cash-flow-rich companies results in a higher dividend yield of 2.16% and lower volatility, with a five-year beta of 0.63. Its expense ratio is 0.38%.

The takeaway from these three funds is clear: they are designed for defense and income. As The Motley Fool notes, big pharma companies tend to be defensive holdings, as people need medicine regardless of the economic climate. This explains the lower volatility and steadier, albeit potentially lower, long-term returns compared to the broader market.

The Growth Plays: IBBQ, BBH, and IBB

On the other side of the trade are the biotech-focused funds, vehicles built for investors willing to stomach gut-wrenching volatility for a shot at outsized gains. The Invesco Nasdaq Biotechnology ETF (IBBQ) holds 253 stocks, with top positions in Vertex Pharmaceuticals (VRTX), Amgen (AMGN), and Gilead Sciences (GILD). Launched in 2021, it’s the newcomer of the group. Its performance has been a roller coaster. Despite its growth mandate, since inception it has returned a total of 35%, a CAGR of 6.2%, underperforming XLV’s 6.9% CAGR in the same window. However, The Motley Fool points out that IBBQ has delivered significantly higher returns over the trailing 12 months. The fund’s expense ratio is 0.19% and its dividend yield is a meager 0.80%.

The VanEck Biotech ETF (BBH) is even more concentrated, holding just 25 companies involved in genetic research and diagnostics. Amgen, Gilead, and Vertex dominate its portfolio. Since 2016, BBH has delivered a total return of 98%, a CAGR of 7.1%, trailing the broader IYH. It carries an expense ratio of 0.35% and yields just 0.50%.

Finally, the iShares Biotechnology ETF (IBB), the oldest of the biotech trio with a 2001 launch, holds 248 companies. Its expense ratio is the highest of the group at 0.44%, and its dividend yield trails the pharmaceutical funds. The Motley Fool describes the core trade-off succinctly: clinical-stage biotech firms plow every available dollar back into research, and their stock prices can swing wildly on a single clinical trial result or FDA decision.

Comparing the Key Metrics

A side-by-side look at the data reveals the stark differences in cost, risk, and income across these strategies.

Fund	Ticker	Expense Ratio	Dividend Yield	5-Year Beta
State Street Health Care Select Sector SPDR ETF	XLV	0.08%	1.60%	0.77
iShares U.S. Healthcare ETF	IYH	0.38%	1.20%	0.79
iShares U.S. Pharmaceuticals ETF	IHE	0.38%	2.16%	0.63
Invesco Nasdaq Biotechnology ETF	IBBQ	0.19%	0.80%	0.91
VanEck Biotech ETF	BBH	0.35%	0.50%	0.85
iShares Biotechnology ETF	IBB	0.44%	0.35%	0.97

Data sourced from The Motley Fool analyses as of July 2026. Beta measures price volatility relative to the S&P 500 based on five-year monthly returns. Dividend yield is the trailing-12-month distribution yield.

Portfolio Fit and Overlap

The reports caution that choosing one of these funds isn’t just a bet on a sector; it’s a decision about portfolio construction. The Motley Fool’s analysis of IHE and IBB notes that the largest holdings in these specialty ETFs are already prominent members of broad market indexes like the S&P 500. An investor with a substantial allocation to a total market fund might inadvertently overweight their healthcare exposure by adding a dedicated ETF like IHE or IBB.

This overlap is particularly acute in the broad healthcare funds. XLV and IYH’s top holdings—Eli Lilly, Johnson & Johnson, and UnitedHealth—are already among the most heavily weighted stocks in the entire U.S. market. For investors seeking true diversification away from market-cap-weighted indexes, a concentrated biotech fund like BBH or a pure-play pharma fund like IHE might offer a more distinct return profile, albeit with greater risk.

The decision ultimately circles back to the individual investor’s goals. As The Motley Fool suggests, someone nearing retirement and looking for income might lean toward the stability and yield of IHE or XLV. A younger investor with a longer time horizon and higher risk tolerance might find the growth potential of IBBQ or IBB more appealing, even with the added volatility. Some may even choose to blend the two, using a broad healthcare fund as a portfolio ballast and a biotech fund as a smaller, higher-octane position.